Table 3: Weighted Average Reductions From Baseline of SBP and DBP and BP Control Rate for Each Aliskiren/HCTZ Combination Commercially Available

Aliskiren/HCTZ Combination Evaluated Number of Clinical Trials Total number of Patients Change in SBP from Baseline at Endpoint (mm Hg) Change in DBP from Baseline at Endpoint (mm Hg) BP Control Rate (%)a
Aliskiren/HCTZ 150/12.5 mg 1 184 -17.6 -11.9 [37.4, 59. 5]a
Aliskiren/HCTZ 150/25 mg 2 429 -15.8 -10.3 [43.8, 53. 5]a
Aliskiren/HCTZ 300/12.5 mg 2 472 -15.9 -11.8 [50.1, 58. 5]a
Aliskiren/HCTZ 300/25 mg 5 966 -16.9±0.4 -11.6±0.3 [51.9, 55. 9]a

Changes in blood pressure are presented as the weighted least-squares mean changes ± SEM (not all variability information was provided in the trial of Villamil (2007) [21], preventing the use of an approximation for SEM or confidence intervals estimation for the first three aliskiren/HCTZ dose combinations).
a The range presented is due to the trial of Villamil (2007) [21], which presented the range of BP control rate for aliskiren/HCTZ combination, without specify the values for each dose combination.
BP – Blood pressure; DBP – Diastolic blood pressure; HCTZ – Hydrochlorothiazide; SBP – Systolic blood pressure.